Form 4: Alnylam Director Hamburg Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Margaret A. Hamburg was granted 671 restricted stock units and 1,441 stock options by Alnylam Pharmaceuticals.
Summary
- Director Margaret A. Hamburg acquired 671 restricted stock units (RSUs) on May 20, 2026.
- Director Hamburg was granted 1,441 stock options with an exercise price of $298.48.
- The equity awards were issued under the Second Amended and Restated 2018 Stock Incentive Plan.
- Both the RSUs and stock options vest in full on the earlier of the first anniversary of the grant date or the director's retirement/resignation (if within 90 days of the anniversary).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Market volatility affecting the value of granted stock options.
- Potential for future dilution if additional equity incentive plans are authorized.
Future Outlook
The equity grants are subject to standard vesting schedules tied to the director's continued service or retirement/resignation within specific timeframes.
Industry Context
StockSavvy.ai notes that standard equity compensation for board members in the biotechnology sector is a common practice to ensure governance alignment and retention of experienced leadership.
Comparison to Industry Standards
- The use of RSUs and stock options for non-employee directors is consistent with standard corporate governance practices for mid-to-large cap pharmaceutical companies.
- Vesting schedules tied to one-year anniversaries are typical for annual director equity refresh grants.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Grant | Grant of RSUs and stock options to Director Margaret A. Hamburg. | 05/20/2026 | Standard compensation adjustment. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity awards on May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of grant for RSUs and stock options. |
| 05/20/2027 | Vesting date for stock options and RSUs. |
| 05/20/2036 | Expiration date for stock options. |
Keywords
Alnylam Pharmaceuticals, ALNY, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.